Atazanavir has a better impact on lipid profiles than Fosamprenavir and Lopinavir in patients matched baseline triglycerides and cholesterol

Abstract

info:eu-repo/semantics/nonPublishe

    Similar works

    Full text

    thumbnail-image

    Available Versions